In navigator, the angiotensin receptor blocker valsartin modestly reduced the progression to type 2 diabetes but had no effect on cardiovascular events in higher-risk patients with impaired glucose tolerance.
Division of General Internal Medicine/Division of Cardiology, University of Nevada School of Medicine, Reno, NV, USA. mbloch@aol.com
Michael J
MJ
Bloch
Jan N
JN
Basile